No Data
No Data
Hengrui Medicine-B (02142) has received a termination notice from Cullinan regarding the termination agreement. Harbour will regain the global rights of HBM7008.
Hua Bo Pharmaceutical - B (02142) issued an announcement that the company received a termination notice from Cullinan regarding the termination of the agreement...
Express News | Hbm Holdings - Received Termination Notice From Cullinan Terminating Agreement
Express News | Hbm Holdings - Collaboration- With Cullinan Therapeutics, Inc. for Hbm7008
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Hua Bo Pharmaceutical - B (02142.HK) plans to hold a board of directors meeting on August 28th to approve the interim performance.
Hepalink Pharmaceutical Group Co., Ltd. - B (02142.HK) announced that the board of directors will hold a meeting on Wednesday, August 28, 2024 to consider and approve the Group's interim performance for the six months ending June 30, 2024, as well as handle other matters.
HBM HOLDINGS-B: DATE OF BOARD MEETING
No Data